Abstracts tagged "Systemic sclerosis"

Abstract Number: 0687 • ACR Convergence 2025
Distinct Cancer Risk Profiles in Patients with Systemic Sclerosis with Autoantibody Stratification
Arjun Mahajan¹, Nikki Zangenah², Maria Vazquez-Machado², Avery LaChance³ and Jeffrey Sparks⁴, ¹Harvard Medical School, Boston, ²Brigham and Women's Hospital, Harvard Medical School, Boston, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with systemic sclerosis (SSc) face increased cancer risk compared to the general population, yet current evidence on specific cancer patterns and their relationship…
Abstract Number: 0883 • ACR Convergence 2025
Predictive Significance of Serum Proteins for the Course of Systemic Sclerosis-Related Interstitial Lung Disease in the Multicenter CONQUER Cohort
Ali Ayla¹, Chenyue Huang², Claudia Pedroza³, Meng Zhang⁴, John VanBuren⁵, Flavia Castelino⁶, Lorinda Chung⁷, Luke Evnin⁸, Tracy Frech⁹, Jessica Gordon¹⁰, Faye Hant¹¹, Laura Hummers¹², Dinesh Khanna¹³, Kimberly Lakin¹⁰, Dorota Lebiedz-Odrobina⁵, Yiming Luo¹⁴, Ashima Makol¹⁵, Maureen Mayes¹⁶, Zsuzsanna McMahan¹⁷, Jerry Molitor¹⁸, Duncan Moore¹⁹, Carrie Richardson²⁰, Nora Sandorfi²¹, Ami Shah¹², Ankoor Shah²², Victoria Shanmugam²³, Brian Skaug¹, Virginia Steen²⁴, Elizabeth Volkmann²⁵, Carleigh Zahn¹³, Wenjin J Zheng², Elana Bernstein¹⁴ and Shervin Assassi²⁶, ¹UTHealth Houston Division of Rheumatology, Houston, TX, ²UTHealth Houston, Houston, ³UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, ⁴UTHealth Houston Division of Rheumatology, Houston, ⁵University of Utah, Salt Lake City, UT, ⁶Massachusetts General Hospital, Boston, MA, ⁷Stanford University, Stanford, CA, ⁸Scleroderma Research Foundation, Brisbane, CA, ⁹Vanderbilt University Medical Center, Nashville, TN, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Johns Hopkins Rheumatology, Baltimore, MD, ¹³University of Michigan, Ann Arbor, MI, ¹⁴Columbia University, New York, NY, ¹⁵Mayo Clinic, Rochester, MN, ¹⁶UT Health Houston Division of Rheumatology, Houston, TX, ¹⁷UT Health Houston, Houston, TX, ¹⁸University of Minnesota, Minneapolis, MN, ¹⁹Northwestern Memorial Hospital, Chicago, IL, ²⁰Northwestern University, Chicago, IL, ²¹University of Pennsylvania, Philadelphia, PA, ²²Duke University, Durham, NC, ²³National Institutes of Health, Great Falls, VA, ²⁴Georgetown University School of Medicine, Washington, DC, ²⁵Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²⁶Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX
Background/Purpose: The course of interstitial lung disease (ILD) in systemic sclerosis (SSc) is highly variable and difficult to predict using clinical variables alone. Therefore, there…
Abstract Number: 0006 • ACR Convergence 2025
QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis
Jenny McGovern, Georgios Eleftheriadis, Thomas Grothier, Eva Bugallo Blanco, Anna Koi, Mahsa Nemani, Cameron Allum, Emily Hurley, Daniela Penston, Marc Martinez-Llordella, Luke Devey and Nathalie Belmonte, Quell Therapeutics, London, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc) are immune mediated inflammatory diseases (IMID) where a complex interplay of tissue and immune cell activation drives…
Abstract Number: 2497 • ACR Convergence 2025
Unraveling the Complexity of Interferon Responses in Peripheral Blood Mononuclear Cells in Systemic Sclerosis at Single-Cell Resolution
Pietro Bearzi¹, Elena Pachera², Astrid Hofman³, Laura Much⁴, Lumeng Li¹, Kristina Bürki³, Cosimo Bruni⁵, Mike Becker⁶, Anna-Maria Hoffmann-Vold⁷, Roberto Giacomelli⁸ and Oliver Distler⁹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zürich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁵University of Zurich, Zurich, Switzerland, ⁶Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ⁷Oslo University Hospital, Oslo, Norway, ⁸i) Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Campus Biomedico; ii) Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome "Campus Bio-Medico", Rome, Italy, ⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Autoimmunity is a hallmark of SSc pathogenesis. Emerging evidence suggests that interferon (IFN) signaling plays a role in predicting SSc patients at risk of…
Abstract Number: 2485 • ACR Convergence 2025
Prevalence of progressive pulmonary fibrosis in systemic sclerosis-associated interstitial lung disease
Javier Narváez¹, Irene Carrión-Barberà², Carlos Valera Ribera³, Alfredo Guillen del Castillo⁴, Laura Tio⁵, Laura Triginer⁶, Lidia Montala-Valencia⁷, Carmen Pilar Simeon⁸, Anna Pros², JUAN JOSE ALEGRE SANCHO⁹ and Joan Miquel Nolla¹⁰, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology. Hospital del Mar, Barcelona, Spain, ³Hospital Universitario Doctor Peset, València, Spain, ⁴Departmend of Internal Medicine. Hospital Universitario Vall d´Hebron, Barcelona, Spain, ⁵Hospital del Mar Research Institute, Barcelona, Spain, ⁶Vall d´Hebron Institut de Recerca (VHIR), Barcelona, Spain, ⁷Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁸Department of Internal Medicine, Hospital Universitario Vall d’Hebron, Barcelona, Spain, ⁹Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, ¹⁰Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain
Background/Purpose: To estimate the prevalence of the progressive pulmonary fibrosis (PPF) phenotype among patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) and identify risk factors…
Abstract Number: 1861 • ACR Convergence 2025
Accelerated and Gene-Specific Patterns of Clonal Hematopoiesis Distinguish Subtypes of Systemic Sclerosis
Brecca Miller¹, Shervin Assassi², Maureen Mayes³, alejandro Molina⁴, Kelly Ruggles⁵, David Beck⁶ and Meng Zhang⁷, ¹Center for Human Genetics and Genomics, NYU Grossman School of Medicine, Brooklyn, NY, ²Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ³UT Health Houston Division of Rheumatology, Houston, TX, ⁴Georgia Institute of Technology, Atlanta, GA, ⁵NYU Grossman School of Medicine, Brooklyn, NY, ⁶Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY, ⁷UTHealth Houston Division of Rheumatology, Houston
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by widespread fibrosis, vasculopathy, autoantibody presence, and high mortality in its diffuse subtype with limited effective…
Abstract Number: 1570 • ACR Convergence 2025
Hydroxychloroquine and Disease Progression in Systemic Sclerosis: Insights from Antibody-Stratified Survival Analyses
Francesco Bonomi¹, Ilaria Bisconti², Ilenia Mallia³, Greta Pellegrino⁴, Gabriele Ciuti⁵, Gloria Muolo², Martina Salerno², Simona Truglia², Cristiano Barbetta³, Silvia Peretti⁵, Serena Guiducci⁶, Valeria Riccieri⁷ and Silvia Bellando Randone³, ¹University Hospital Careggi, Florence, Florence, Toscana, Italy, ²Sapienza University of Rome, Rome, Rome, Italy, ³University of Florence, Florence, Italy, ⁴Rheumatology Unit, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milano, Italy; Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, ⁵University Hospital Careggi, Florence, Italy, ⁶Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, Italy, ⁷Sapienza University of Rome, Rheumatology Clinic, Rome, Italy, Roma, Italy
Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial drug that interferes with dendritic cells and monocytes, acidifies endosomes, and modulates toll-like receptors, reducing autoimmune responses and cell…
Abstract Number: 1037 • ACR Convergence 2025
Risk Factor Identification and Dynamic Individualized Prediction of Muscle Involvement in Systemic Sclerosis
Zixing Liu¹, Adrianne Woods², Julie Paik², Laura Hummers², Scott Zeger¹, Ami Shah² and Ji Soo Kim³, ¹Johns Hopkins Biostatistics, Baltimore, MD, ²Johns Hopkins Rheumatology, Baltimore, MD, ³Johns Hopkins, Baltimore, MD
Background/Purpose: Myopathy in SSc significantly increases disability, reduces quality of life, and elevates mortality risk, yet remains understudied. Most identified risk factors derive from cross-sectional…
Abstract Number: 0960 • ACR Convergence 2025
Pharmaceutical Blockade of the Neonatal Fc Gamma Receptor Ameliorates Autoimmunity, Inflammation and Fibrosis in the Topoisomerase I Mouse Model of Systemic Sclerosis
Cuong Tran-Manh¹, Thuong Trinh-Minh², Christoph Liebel³, Bas van der Woning⁴, Piotr Zabrocki⁵ and Jörg Distler⁶, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Nordrhein-Westfalen, Germany, ²Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁴argenx BV, Boston, MA, ⁵argenx, Ghent, Belgium, ⁶University Hospital Duesseldorf and HHU, Duesseldorf, Germany
Background/Purpose: SSc is a rare, chronic, systemic autoimmune rheumatic disease characterized by progressive skin and internal organ fibrosis, severe vasculopathy and immune dysregulation with production…
Abstract Number: 0686 • ACR Convergence 2025
Use of a Smartphone App which Incorporates Feedback to Patients to Monitor Systemic Sclerosis-related Digital Ulcers – a Potential New Tool for Remote Clinical Monitoring
Ariane Herrick¹, Paul New², Graham Dinsdale³, Andy Vail², Joanne Manning³, Michael Hughes⁴, Will dixon⁵, Chris Taylor⁵, Mark Dickinson⁵ and Andrea Murray⁶, ¹The University of Manchester, UK, Aberdeen, United Kingdom, ²The University of Manchester, Manchester, United Kingdom, ³Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom, ⁴Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ⁵The University of Manchester, Manchester, ⁶University of Manchester, Salford, United Kingdom
Background/Purpose: To facilitate clinical trials we previously developed a smartphone app to allow ‘tracking’ of systemic sclerosis (SSc)-related digital ulcers (DUs) and their associated pain…
Abstract Number: 0882 • ACR Convergence 2025
Serum KL-6 as a Predictive Biomarker for Interstitial Lung Disease Progression and Mortality in Systemic Sclerosis: A Prospective Cohort Study
cristiana Sieiro¹, Jose Ordas Martínez², Sara Calleja Antolín², Juan Garcia Herrero², Javier De la Calle², Miriam Retuerto², Laura Sierra², Elena Bollo de Miguel² and Elvira Díez Álvarez², ¹Univrsity of Manchester, Manchester, United Kingdom, ²Complejo Asistencial Universitario de León, León, Spain
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of morbidity and mortality in systemic sclerosis (SSc). Early detection and continuous monitoring of ILD are…
Abstract Number: 0002 • ACR Convergence 2025
KITE-363: An Autologous Anti-CD19/CD20 CAR-T Product for the Treatment of Autoimmune Rheumatic Diseases
Brian Kim, Christine Lowe, Francisco Flores, Jeremy Margaitis, Alessandro Calo, Stacey Valny, Anna Konecny, Eva Jaghatspanyan, Sean Yoder, Kenneth Ertel, Simone Filosto, Jodi Murakami and David Barrett, Kite, a Gilead Company, Santa Monica, CA
Background/Purpose: B-cell dysregulation is a key factor in the development and progression of autoimmune diseases, and B-cell inhibition has been a cornerstone of treatment for…
Abstract Number: 2496 • ACR Convergence 2025
Comparing Long-term Outcome Across Systemic Sclerosis Subgroups Using a Multi-Organ Disease Progression Score
Philip Yee¹, medha kanitkar², stefano rodolfi³, Voon H. Ong² and Christopher Denton⁴, ¹Division of Medicine, Centre for Rheumatology, University College London, London, England, United Kingdom, ²Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ³University College London, London, United Kingdom, ⁴University College London, UK, London, United Kingdom
Background/Purpose: Evaluating disease modification in systemic sclerosis (SSc) is challenging and requires long term studies. This is especially relevant to limited cutaneous (lc)SSc where severe…
Abstract Number: 2472 • ACR Convergence 2025
Digesting the data: tracking gastro-intestinal manifestations in systemic sclerosis over time
Cosimo Bruni¹, Jasmin Klöti², Aurora Maria Tatu³, Lea Stamm², Rucsandra Dobrota⁴, Muriel Elhai⁵, Mike Becker⁶, Sinziana Muraru⁷, Gesa Sauer⁸, Anna-Maria Hoffmann-Vold⁹, Oliver Distler¹⁰ and Carina Mihai¹¹, ¹University of Zurich, Zurich, Switzerland, ²Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³Department of Gastroenterology, University Hospital Zurich, University of Zurich, ⁸⁰⁹¹, Switzerland, ⁴Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁵University Hospital zurich, Zürich, Switzerland, ⁶Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ⁷University of Zurich, University Hospital Zurich, Zürich, Switzerland, ⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, zurich, Switzerland, ⁹Oslo University Hospital, Oslo, Norway, ¹⁰Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹¹University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Gastrointestinal (GI) involvement is among the most frequent organ manifestations in systemic sclerosis (SSc), yet the timing of presentation of GI manifestations remains incompletely…
Abstract Number: 1856 • ACR Convergence 2025
Spatial Proteomic-based Phenotyping of Fibroblast Populations and their Microenvironment in Systemic Sclerosis Primary Heart Involvement
Ayla Nadja Stuetz¹, Giacomo de Luca², Alexandru-Emil Matei³, Yi-Nan Li⁴, Veronica Batani², Tim Filla⁵, Aleix Rius Rigau⁶, Bilgesu Safak Tümerdem¹, Cosimo Bruni⁷, Maike Büttner-Herold⁸, Stefania Rizzo⁹, Monica De Gaspari⁹, Markus Eckstein¹⁰, Georg Schett¹¹, Cristina Basso⁹, Jörg Distler¹², Marco Matucci-Cerinic¹³ and Andrea-Hermina Györfi¹⁴, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ²Vita-Salute San Raffaele University. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ⁴University Hospital of Düsseldorf, Düsseldorf, Germany, ⁵Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁶Department of Internal Medicine ³, Rheumatology and Clinical Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen. Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Department of Nephropathology, University Hospital Erlangen, Erlangen, Germany, ⁹Cardiovascular Pathology Unit, Department of Cardiac, Thoracic and Vascular Sciences, University and Hospital of Padua, Padua, Italy, ¹⁰Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ¹¹Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹²University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹³University San Raffaele Milano, Milano, Milan, Italy, ¹⁴Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany
Background/Purpose: Primary heart involvement (pHI) is one of the leading causes of death in systemic sclerosis (SSc). However, the cellular and molecular pathomechanisms of SSc-pHI…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].